AbbVie’s atogepant meets primary and secondary endpoints in phase 3 trial
AbbVie said its migraine drug atogepant met primary and secondary endpoints in a phase 3 trial for preventive treatment of menstrual migraines. The study reduced migraine days by 1.2 days on average versus 0.4 days.
AbbVie said its migraine drug met the primary and secondary endpoints in a phase 3 trial evaluating it as a preventive treatment for menstrual migraines. 4 days in the comparison group. The trial enrolled 3 participants.